Abstract:E3 ubiquitin ligases, especially the SCF (Skpl-Cull-F-box protein) and APC (Anaphase-promoting complex, also known as APC/C), have been extensively studied in the past decades, These two ubiquitin E3 ligases primarily function in the regulation of cell cycle progression through timely and coordinated degradation of key cell cycle regulators. Mounting evidence has revealed not only that the SCF plays a critical role in tutnorigenesis but also that the APC is important for cancer development. Genetically modified mouse models have demonstrated that the APC co-activator Cdh1 primarily functions as a tumor suppressor, while another co-activator, Cdc20, exhibits an oncogenic role. Consistently, Cdh1 is frequently lost or inactivated in human cancers (Bassennann et al., Cell 134(2):256-267, 2008; Fujita et al,, Clin Cancer Res 14(7):1966-1975, 2008; Fujita et al,, Am J Pathol 173(1):217-228, 2008), while the overexpression of Cdc20 is observed in human malignancies (Mondal et al., Carcinogenesis 28(1):81-92, 2007; Jiang et al., Biochem Biophys Res Comtnun 415(2):325-329, 2011; Rajkumar et al., BMC Cancer 1E80, 2011; Chang et al., J Hematol Oncol 5:15, 2012; Kato et al,, J Surg Oncol 106(4):423-430, 2012). Here, we discuss the identified substrates of APC, and summarize the reported phenotypes of genetically modified mouse models, which support the role of APC in the pathogenesis of human cancers and other relevant human diseases. Finally, we offer perspectives for developing APC pathway-specific inhibitors to treat various types of human cancers.

The Role Of Apc E3 Ubiquitin Ligase Complex In Tumorigenesis